LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Neutral 60.2%

Neg 0% Neu 60.2% Pos 0%

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.